EUDEMINE INJECTION
SH2B1 Deficiency Obesity
Soleno Therapeutics, Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the SH2B1 Deficiency Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dccr Soleno Therapeutics, Inc. | Phase 2 | CCC |
Same molecule, other indications
EUDEMINE INJECTION is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →